Regulus Therapeutics LLC RGLS:NASDAQ

Notable Quotes

"By the end of 2014, you're going to have some pretty good news flow out of BDSI." (4/24/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More�>

"ARNI's onapristone could legitimately be considered a pipeline in a single product." (4/22/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More�>

"THLD's soft-tissue sarcoma study should read out at the end of 2015; that could be a very exciting time." (4/24/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More�>

"CUR's science is cutting edge, and of a very high quality." (4/22/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More�>

"The Phase 2 trial for VGX-3100 could be a major clinical validation of the power of INO's broadly applicable platform." (4/24/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More�>

Companies

Last:
Change:		Change(%):
Volume:		Open:
High:		Low:
52Wk High:		52Wk Low:

Regulus Therapeutics LLC

TICKER: RGLS:NASDAQ

Would you like more information on this company?

First Name *

Last Name

Email *

Phone

* Required

In addition, I would like to receive The Life Sciences Report Newsletter

Fact sheets, annual reports, webinars, CEO interviews and more, may be available for this company. Fill out this form and your contact information will be shared with this company to provide you with additional information.